# EMBioSys

Source: https://onco.cc/companies/embiosys/  
OnCo record `embiosys` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EMBioSys is developing Efinia, a washable tank top that delivers a low-intensity electric field to breast tumours at home. It is an investigational device and has not been cleared by the FDA.

## Summary

EMBioSys develops low-intensity induced electric field therapy (iEF therapy) delivered by Efinia, an electrode-free, battery-powered tank-top garment intended for use at home, aimed initially at breast cancer during the wait for surgery. The device is investigational and not FDA cleared. In fiscal year 2026 NCI awarded it USD 870,482 under SBIR award 5R44CA310518-02 for CuRrEnT, a study of capecitabine with the wearable device in triple-negative breast cancer with residual cancer burden after neoadjuvant treatment.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: EMBIOSYS INC.; EMBioSys Inc.
- HQ: North Andover, MA
- Type: devices
- Website: https://embiosys.com/

## Notes

- Read on embiosys.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://embiosys.com/
- EMBioSys: Efinia: https://embiosys.com/our-therapy
- NIH RePORTER: SBIR award 5R44CA310518-02: https://reporter.nih.gov/project-details/11418087

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- fronts: [Devices & Physical Therapies](https://onco.cc/fronts/devices/)
- drugs: [Efinia](https://onco.cc/drugs/efinia/)

---
JSON: https://onco.cc/api/v1/entities/embiosys.json